Allogeneic transplantation for multiple myeloma: yes, no or maybe?
Bruno B et al. Bone Marrow Transplant. 2016 Feb 22. doi: 10.1038/bmt.2016.12. [Epub ahead of print].

Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience.
Zhou X et al. Hematology. 2016 Feb 22. [Epub ahead of print].

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
Lee HC et al. Curr Hematol Malig Rep. 2016 Feb 22. [Epub ahead of print].

Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.
Nathwani N et al. Curr Hematol Malig Rep. 2016 Feb 18. [Epub ahead of print].

Body size in early life and risk of lymphoid malignancies and histological subtypes in adulthood.
Yang TO et al. Int J Cancer. 2016 Feb 16. doi: 10.1002/ijc.30044. [Epub ahead of print].

Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.
Lu J et al. Leuk Lymphoma. 2016 Feb 17:1-5. [Epub ahead of print].

Risk Stratification in Multiple Myeloma.
Ooi MG et al. Curr Hematol Malig Rep. 2016 Feb 16. [Epub ahead of print].

A wrong move in an amateur football player reveals a light chain myeloma.
Peyneau M et al. Ann Biol Clin (Paris). 2016 Feb 1;74(1):103-105.

Risk of Skin Cancer in Multiple Myeloma Patients: A Retrospective Cohort study.
Robinson AA et al. Eur J Haematol. 2016 Feb 13. doi: 10.1111/ejh.12748. [Epub ahead of print].

Early mortality in multiple myeloma: Experiences from a single institution.
Chen YK et al. Hematology. 2016 Feb 11. [Epub ahead of print].

Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I et al. Eur J Cancer Care (Engl). 2016 Feb 10. doi: 10.1111/ecc.12452. [Epub ahead of print].

FDA approves three different multiple myeloma drugs in one month.
Ratner M et al. Nat Biotechnol. 2016 Feb 5;34(2):126. doi: 10.1038/nbt0216-126.

Cost of skeletal complications from bone metastases in six European countries.
Pereira J et al. J Med Econ. 2016 Feb 5:1-21. [Epub ahead of print].

Meditation for adults with haematological malignancies.
Salhofer I et al. Cochrane Database Syst Rev. 2016 Feb 3;2:CD011157. [Epub ahead of print].

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.
Armenian SH et al. J Clin Oncol. 2016 Feb 1. pii: JCO640409. [Epub ahead of print].

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
Delgado-Calle J et al. Cancer Res. 2016 Feb 1. [Epub ahead of print].

Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.
Greig SL. Target Oncol. 2016 Feb;11(1):107-14. doi: 10.1007/s11523-015-0413-6.